Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
Trifluridine/tipiracil combined with bevacizumab, as a third-line treatment for colorectal cancer, does not have a cost-effectiveness advantage compared to trifluridine/tipiracil monotherapy in economic evaluations.
Authors
- Ling Huang (ORCID: https://orcid.org/0000-0001-5584-0419)
- Hao Gu (ORCID: https://orcid.org/0000-0002-0204-2875)
- Yaqing Chen (ORCID: https://orcid.org/0009-0007-6308-5637)
- Yong Chen (ORCID: https://orcid.org/0000-0001-5857-6086)
Institutions
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2024-11-13
- DOI
- https://doi.org/10.3389/fpubh.2024.1465898
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28